Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study

BACKGROUND: Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced cytokine release syndrome and it may provide clinical benefit for selected COVID–19 patients. METHODS: In this retrospective cohort study, we analyzed hypoxic COVID–19 patients who were consecutively admitted b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kewan, Tariq, Covut, Fahrettin, Al–Jaghbeer, Mohammed J., Rose, Lori, Gopalakrishna, K.V., Akbik, Bassel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305505/
https://www.ncbi.nlm.nih.gov/pubmed/32766537
http://dx.doi.org/10.1016/j.eclinm.2020.100418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305505/
https://www.ncbi.nlm.nih.gov/pubmed/32766537
http://dx.doi.org/10.1016/j.eclinm.2020.100418

Ejemplares similares